{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:39:38Z","timestamp":1781192378015,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>To investigate the role of intensity modulated proton therapy (IMPT) compared to volumetric modulated arc therapy (VMAT) for advanced supradiaphragmatic Hodgkin\u2019s lymphoma (HL) in young female patients by assessing dosimetric features and modelling the risk of treatment related complications and radiation-induced secondary malignancies.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A group of 20 cases (planned according to the involved-site approach) were retrospectively investigated in a comparative planning study. Intensity modulated proton plans (IMPT) were compared to VMAT RapidArc plans (RA). Estimates of toxicity were derived from normal tissue complication probability (NTCP) calculations with either the Lyman or the Poisson models for a number of endpoints. Estimates of the risk of secondary cancer induction were determined for lungs, breasts, esophagus and thyroid. A simple model-based selection strategy was considered as a feasibility proof for the individualized selection of patients suitable for proton therapy.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>IMPT and VMAT plans resulted equivalent in terms of target dose distributions, both were capable to ensure high coverage and homogeneity. In terms of conformality, IMPT resulted ~\u200910% better than RA plans. Concerning organs at risk, IMPT data presented a systematic improvement (highly significant) over RA for all organs, particularly in the dose range up to 20Gy. This lead to a composite average reduction of NTCP of 2.90\u2009\u00b1\u20092.24 and a reduction of 0.26\u2009\u00b1\u20090.22 in the relative risk of cardiac failures. The excess absolute risk per 10,000 patients-years of secondary cancer induction was reduced, with IMPT, of 9.1\u2009\u00b1\u20093.2, 7.2\u2009\u00b1\u20093.7 for breast and lung compared to RA. The gain in EAR for thyroid and esophagus was lower than 1. Depending on the arbitrary thresholds applied, the selection rate for proton treatment would have ranged from 5 to 75%.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>In relation to young female patients with advanced supradiaphragmatic HL, IMPT can in general offer improved dose-volume sparing of organs at risk leading to an anticipated lower risk of early or late treatment related toxicities. This would reflect also in significantly lower risk of secondary malignancies induction compared to advanced photon based techniques. Depending on the selection thresholds and with all the limits of a non-validated and very basic model, it can be anticipated that a significant fraction of patients might be suitable for proton treatments if all the risk factors would be accounted for.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13014-020-1462-2","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T18:03:17Z","timestamp":1578938597000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin\u2019s lymphoma. Assessment of risk of toxicity and secondary cancer induction"],"prefix":"10.1186","volume":"15","author":[{"given":"Marta","family":"Scorsetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7862-898X","authenticated-orcid":false,"given":"Luca","family":"Cozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierina","family":"Navarria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Fogliata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorenza","family":"De Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Franzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Carlo-Stella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,13]]},"reference":[{"key":"1462_CR1","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1007\/s00066-014-0719-9","volume":"190","author":"F Lohr","year":"2014","unstructured":"Lohr F, Georg D, Cozzi L, Eich HT, Weber DC, Koeck J, et al. Novel radiotherapy techniques for involved-field and involved-node treatment of mediastinal Hodgkin lymphoma: when should they be considered and which questions remain open? Strahlenther Onkol. 2014;190:864\u20136.","journal-title":"Strahlenther Onkol"},{"key":"1462_CR2","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.ijrobp.2017.05.004","volume":"99","author":"Y Tseng","year":"2017","unstructured":"Tseng Y, Cutter D, Plastaras J, Parikh R, Cahlon O, Chuong M, et al. Evidence-based review on the use of proton therapy in lymphoma from the particle therapy cooperative group (PTCOG) lymphoma subcommittee. Int J Radiat Oncol Biol Phys. 2017;99:825\u201342.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1462_CR3","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1182\/blood-2018-03-837633","volume":"132","author":"B Dabaja","year":"2018","unstructured":"Dabaja B, Hoppe B, Plastaras J, Newhauser W, Rosolova K, Flampouri S, et al. Proton therapy for adults with mediastinal lymphomas: the international lymphoma radiation oncology group guidelines. Blood. 2018;132:1635\u201346.","journal-title":"Blood"},{"key":"1462_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.prro.2019.01.006","volume":"9","author":"G Ntentas","year":"2019","unstructured":"Ntentas G, Dedeckova K, Andrlik M, Aznar M, George B, Kubes J, et al. Clinical intensity modulated proton therapy for Hodgkin lymphoma: which patients benefit the most? Pract Radiat Oncol. 2019;9:179\u201387.","journal-title":"Pract Radiat Oncol"},{"key":"1462_CR5","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13014-018-1066-2","volume":"13","author":"C Baues","year":"2018","unstructured":"Baues C, Marnitz S, Engert A, Baus W, Jablonska K, Fogliata A, et al. Proton versus photon DEEP inspiration breath hold technique in patients with hodgkin lymphoma and mediastinal radiation : a PLANNING COMPARISON OF DEEP INSPIRATION BREATH HOLD INTENSITY MODULATION RADIOTHERAPY AND INTENSITY MODULATED PROTON THERAPY. Radiat Oncol. 2018;13:122.","journal-title":"Radiat Oncol"},{"issue":"6","key":"1462_CR6","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.prro.2019.05.009","volume":"9","author":"A Everett","year":"2019","unstructured":"Everett A, Hoppe B, Louis D, McDonald A, Morris C, Mendenhall N, et al. Comparison of Techniques for Involved-Site Radiation Therapy in Patients with Lower Mediastinal Lymphoma. Pract Radiat Oncol. 2019;9(6):426\u201334.","journal-title":"Pract Radiat Oncol"},{"issue":"7","key":"1462_CR7","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00066-019-01460-7","volume":"195","author":"L K\u00f6nig","year":"2019","unstructured":"K\u00f6nig L, Bougatf N, H\u00f6rner-Rieber J, Chaudhri N, Mielke T, Kl\u00fcter S, et al. Consolidative mediastinal irradiation of malignant lymphoma using active scanning proton beams: clinical outcome and dosimetric comparison. Strahlenther Onkol. 2019;195(7):677\u201387.","journal-title":"Strahlenther Onkol"},{"key":"1462_CR8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/0284186X.2018.1512153","volume":"58","author":"A Edvardsson","year":"2019","unstructured":"Edvardsson A, K\u00fcgele M, Alkner S, Enmark M, Nilsson J, Kristensen I, et al. Comparative treatment planning study for mediastinal Hodgkin's lymphoma: impact on normal tissue dose using deep inspiration breath hold proton and photon therapy. Acta Oncol. 2019;58:95\u2013104.","journal-title":"Acta Oncol"},{"key":"1462_CR9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.semradonc.2017.11.008","volume":"28","author":"J Langendijk","year":"2018","unstructured":"Langendijk J, Boersma J, Rasch C, van Vulpen M, Reitsma J, van der Schaaf A, et al. Clinical trial strategies to compare protons with photons. Semin Radiat Oncol. 2018;28:79\u201387.","journal-title":"Semin Radiat Oncol"},{"key":"1462_CR10","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.radonc.2013.05.007","volume":"107","author":"J Langendijk","year":"2013","unstructured":"Langendijk J, Lambin P, De Ruysscher D, Widder J, Bos M, Verhaij M. Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol. 2013;107:267\u201373.","journal-title":"Radiother Oncol"},{"key":"1462_CR11","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ijrobp.2018.12.055","volume":"104","author":"J Rwigema","year":"2019","unstructured":"Rwigema J, Langendijk J, van der Laan P, Lukens J, Swisher-McClure S, Lin A. A model based approach to predict short term toxicity benefits with proton therapy for oropharyngeal cancer. Int J Radiat Oncol Biol Phys. 2019;104:553\u201362.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1462_CR12","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.radonc.2016.08.022","volume":"121","author":"P Blanchard","year":"2016","unstructured":"Blanchard P, Wong A, Gunn F, et al. Toward a model based patient selection strategy for proton therapy: external validation of photon derived normal tissue complication probability models in a head and neck proton therapy cohort. Radiother Oncol. 2016;121:381\u20136.","journal-title":"Radiother Oncol"},{"key":"1462_CR13","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.radonc.2015.12.029","volume":"118","author":"Q Cheng","year":"2016","unstructured":"Cheng Q, Roelofs E, Ramaekers B, Eekers D, van Soest J, Lustberg T, et al. Development and evaluation of an online three level proton vs photon decision support prototype for head and neck cancer \u2013 comparison of dose, toxicity and cost-effectiveness. Radiother Oncol. 2016;118:281\u20135.","journal-title":"Radiother Oncol"},{"key":"1462_CR14","doi-asserted-by":"crossref","unstructured":"Prayongrat A, Kobashi K, Ito Y, Katoh N, Tamura M, Dekura Y, et al. The normal tissue complication probability mode-based approach considering uncertainties for the selective use of radiation modality in primary liver cancer patients. Radiother Oncol. 2019:135\u201306.","DOI":"10.1016\/j.radonc.2019.03.003"},{"key":"1462_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.radonc.2017.07.033","volume":"125","author":"L Rechner","year":"2017","unstructured":"Rechner L, Maraldo M, Vogelius I, Zhu X, Dabaja B, Brodin N, et al. Life years lost attributable to late effects after radiotherapy for early stage Hodgkin lymphoma: the impact of proton therapy and\/or deep inspiration breath hold. Radiother Oncol. 2017;125:41\u20137.","journal-title":"Radiother Oncol"},{"key":"1462_CR16","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1259\/0007-1285-69-825-839","volume":"69","author":"G Gagliardi","year":"1996","unstructured":"Gagliardi G, Lax I, Ottolenghi A, Rutqvist L. Long-term cardiac mortality after radiotherapy of breast cancer application of the relative seriality model. Br J Radiol. 1996;69:839\u201346.","journal-title":"Br J Radiol"},{"key":"1462_CR17","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/S0360-3016(02)03986-X","volume":"55","author":"Y Seppenwoolde","year":"2003","unstructured":"Seppenwoolde Y, Lebesque J, de Jaeger K, de Jaeger J, Boersma L, Schilstra C, et al. Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability. Int J Radiat Oncol Biol Phys. 2003;55:724\u201335.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1462_CR18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0167-8140(03)00003-3","volume":"67","author":"V Moiseenko","year":"2003","unstructured":"Moiseenko V, Craig T, Bezjak A, Van Dyk J. Dose-volume analysis of lung complications in the radiation treatment of malignant thymoma: a retrospective review. Radiother Oncol. 2003;67:265\u201374.","journal-title":"Radiother Oncol"},{"key":"1462_CR19","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.radonc.2005.10.001","volume":"77","author":"O Chapet","year":"2005","unstructured":"Chapet O, Kong F, Lee J, Hayman J, Ten Haken R. Normal tissue complication probability for acute esophagitis in patients treated with conformal radiation therapy for non small cell lung cancer. Rad Onc. 2005;77:176\u201381.","journal-title":"Rad Onc"},{"key":"1462_CR20","unstructured":"Nocedal J, Wright S. Numerical Optimization, Second Edition. 2006. ISBN-13:978-0387-30303-1."},{"key":"1462_CR21","doi-asserted-by":"publisher","first-page":"e0201992","DOI":"10.1371\/journal.pone.0201992","volume":"13","author":"L Cozzi","year":"2018","unstructured":"Cozzi L, Comito T, Fogliata A, Franzese C, Tomatis S, Scorsetti M. Critical appraisal of the potential role of intensity modulated proton therapy in the hypofractionated treatment of advanced hepatocellular carcinoma. PLoS One. 2018;13:e0201992.","journal-title":"PLoS One"},{"key":"1462_CR22","doi-asserted-by":"crossref","unstructured":"AA.VV. ICRU Report 83. Prescribing recording and reporting photon beam intensity modulated radiation therappy (IMRT). Volume 10 number 1. 2010.","DOI":"10.1093\/jicru\/ndq002"},{"key":"1462_CR23","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.2307\/3576626","volume":"104","author":"J Lyman","year":"1985","unstructured":"Lyman J. Complication probability as assessed from dose volume histograms. Radiat Res. 1985;104:S13\u20139.","journal-title":"Radiat Res"},{"key":"1462_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/09553009214552071","volume":"62","author":"P K\u00e4llman","year":"1992","unstructured":"K\u00e4llman P, \u00c5gren A, Brahme A. Tumour and normal tissue responses to fractionated non-uniform dose delivery. Int J Radiat Biol. 1992;62:149\u2013262.","journal-title":"Int J Radiat Biol"},{"key":"1462_CR25","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","volume":"34","author":"F van Nimwegen","year":"2016","unstructured":"van Nimwegen F, Schaapveld M, Cutter D, Janus C, Krol A, Hauptmann M, et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol. 2016;34:235\u201343.","journal-title":"J Clin Oncol"},{"key":"1462_CR26","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1182\/blood-2016-09-740332","volume":"129","author":"F van Nimwegen","year":"2018","unstructured":"van Nimwegen F, Ntentas G, Darby S, Schaapveld M, Hauptmann M, Lugtenburg P, et al. Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. Blood. 2018;129:2257\u201365.","journal-title":"Blood"},{"key":"1462_CR27","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa1209825","volume":"368","author":"S Darby","year":"2013","unstructured":"Darby S, Ewertz M, McGale P, Bennet A, Blom-Goldman U, Br\u00f8nnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:987\u201398.","journal-title":"N Engl J Med"},{"key":"1462_CR28","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.radonc.2019.05.009","volume":"138","author":"M Levis","year":"2019","unstructured":"Levis M, Filippi A, Fiandra C, De Luca V, Bartoncini S, Vella D, et al. Inclusion of heart substructures in the optimization process of volumetric modulated arc therapy techniques may reduce the risk of heart disease in Hodgkin\u2019s lymphoma patients. Radiother Oncol. 2019;138:52\u20138.","journal-title":"Radiother Oncol"},{"key":"1462_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1667\/RR0763.1","volume":"168","author":"D Preston","year":"2007","unstructured":"Preston D, Ron E, Tokuoka S, Funamoto S, Nishi N, Soda M, et al. Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res. 2007;168:1\u201364.","journal-title":"Radiat Res"},{"key":"1462_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1742-4682-8-27","volume":"8","author":"U Schneider","year":"2011","unstructured":"Schneider U, Sumila M, Robotka J. Site-specific dose-response relationships for cancer induction from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy. Theor Biol Med Mod. 2011;8:27.","journal-title":"Theor Biol Med Mod"},{"key":"1462_CR31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1748-717X-6-67","volume":"6","author":"U Schneider","year":"2011","unstructured":"Schneider U, Sumila M, Robotka J, Gruber G, Mack A, Besserer J. Dose-response relationship for breast cancer induction at radiotherapy dose. Radiat Oncol. 2011;6:67.","journal-title":"Radiat Oncol"},{"key":"1462_CR32","unstructured":"Mihai Marian Tomozeiu \"Modeling a dose-response relationship for thyroid cancer at radiotherapy dose levels\", MSc thesis ETH Z\u00fcrich 2012."},{"key":"1462_CR33","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1093\/annonc\/mdx287","volume":"28","author":"B Hoppe","year":"2017","unstructured":"Hoppe B, Hill-Kayser C, Tseng Y, Flampouri S, Elmongy H, Cahlon O, et al. Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma. Ann Oncol. 2017;28:2179\u201384.","journal-title":"Ann Oncol"},{"key":"1462_CR34","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ijrobp.2009.10.058","volume":"79","author":"M Feng","year":"2011","unstructured":"Feng M, Moran J, Koelling T, Chughtai A, Chan J, Freedman L, et al. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int Radiat Oncol Biol Phys. 2011;79:10\u20138.","journal-title":"Int Radiat Oncol Biol Phys"},{"key":"1462_CR35","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1667\/RR2240.1","volume":"174","author":"P Bhatti","year":"2010","unstructured":"Bhatti P, Veiga L, Ronckers C, Sigurdson A, Stovall M, Smith S, et al. Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the childhood cancer survivor study. Radiat Res. 2010;174:741\u201352.","journal-title":"Radiat Res"},{"key":"1462_CR36","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1080\/0284186X.2016.1191665","volume":"55","author":"C Zeng","year":"2016","unstructured":"Zeng C, Plastaras J, James P, Tochner Z, Hill-Kayser C, Hahn S, et al. Proton pencil beam scanning for mediastinal lymphoma: treatment planning and robustness assessment. Acta Oncol. 2016;55:1132\u20138.","journal-title":"Acta Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-020-1462-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13014-020-1462-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-020-1462-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T01:14:08Z","timestamp":1610414048000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-020-1462-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,13]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1462"],"URL":"https:\/\/doi.org\/10.1186\/s13014-020-1462-2","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,13]]},"assertion":[{"value":"1 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The retrospective study has been approved by notification by the local ethics committee. Wherever necessary informed consent from the patients has been obtained.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval andconsent to participate"}},{"value":"Not applicable:","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"L. Cozzi acts as Scientific Advisor to Varian Medical Systems and is Clinical Research Scientist at Humanitas Cancer Center. All other co-authors declare that they have no conflict interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}